Health Catalyst (HCAT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Jun, 2026Voting matters and shareholder proposals
Election of two Class I Directors for a three-year term until the 2029 Annual Meeting or until successors are elected and qualified.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Advisory, non-binding vote to approve the compensation of named executive officers.
Approval of the restatement of the Certificate of Incorporation to phase out the classified board structure, moving to annual director elections starting with the 2029 Annual Meeting.
Proxies authorized to transact other business as may properly come before the meeting.
Board of directors and corporate governance
Proposal to phase out the classified board structure, transitioning to annual elections for all directors elected at or after the 2029 Annual Meeting.
Executive compensation and say-on-pay
Advisory, non-binding vote on the compensation of named executive officers is included as a voting item.
Latest events from Health Catalyst
- Q2 2026 revenue fell 13%, adjusted EBITDA rose, and divestiture enabled full debt repayment.HCAT
Q2 2026 - Director elections, auditor ratification, and executive pay approved; board structure change failed.HCAT
AGM 2026 - Board seeks approval for director elections, auditor ratification, executive pay, and declassification.HCAT
Proxy filing - Proxy covers director elections, auditor ratification, say-on-pay, and board declassification.HCAT
Proxy filing - Q1 2026 saw $70.8M revenue, $9.1M adjusted EBITDA, and a $95.5M goodwill impairment widening net loss.HCAT
Q1 2026 - Q3 2025 revenue flat at $76.3M, Adjusted EBITDA up 64%, net loss widened on non-recurring charges.HCAT
Q3 2025 - Q3 revenue up 3% to $76.4M, adjusted EBITDA $7.3M, and full-year outlook raised.HCAT
Q3 2024 - Q2 revenue up 4% to $75.9M, EBITDA rose, net loss narrowed, and record new client growth achieved.HCAT
Q2 2024 - Q1 revenue up 6% to $79.4M, Adjusted EBITDA rose, Upfront acquired, guidance reiterated.HCAT
Q1 2025